Slide 1: withZeta.ai: Discover Therapies & Develop Insights for Rare Cancers
withZeta.al Discover Therapies & Develop Insights for Rare Cancers — at the Speed of Thought | Multi-Agentic, Multi-Tool Al Architecture | 438+ Rare Cancer Disease Entities | Accessible to Any Investigator, Anywhere BUILT BY @)Lantempharma @ withZETA
Slide 2: The Market Has Failed Rare Cancer Patients — Until Now
THE RARE CANCER CHALLENGE The Market Has Failed Rare Cancer Patients — Until Now $ 1 2 B Drug development cost — regardless of ~ patient population size 5 M ae Rare cancer patients globally with few or no approved treatments curated knowledge base | 438 Distinct rare cancer types in withZeta's WITHZ
Slide 3: A Network of AI Agents, Working in Concert
MULTI-AGENTIC ARCHITECTURE A Network of Al Agents, Working in Concert withZeta doesn't retrieve and repackage information. It generates net-new scientific knowledge — advancing understanding in ways that accelerate the path from hypothesis to clinic. PubMed, clinical trial registries & regulatory Re
Slide 4: Multiple Research Modes
MULTI-AGENTIC ARCHITECTURE @ withZETA Multiple Research Modes withZeta offers three research modes that you can switch between at any time based on needs. * Provides fast, conversational research for iterative dialogue and quick insights ® Explorer + Ideal for brainstorming, initial exploration, and
Slide 5: Your Co-Scientist, Tuned to How You Think
® with ZETA CO-SCIBIMITIST P ERRSyO N ARS Your Co-Scientist, Tuned to How You Think General Research Scientist Broad rare cancer expertise - literature synthesis - exploratory research Medicinal Chemist De novo drug design - SAR analysis - ADMET prediction - molecular optimization regulatory strateg
Slide 6: What You're About to See: Live Discovery in Real Time
TODAY'S LIVE DEMO What You're About to See: Live Discovery in Real Time Co-scientist persona selection & research mode overview | 01 Platform Orientation Rare Cancer Query 02 Real-time multi-agent investigation across PubMed, trials & pathway databases | 03 Knowledge Graph in Action 3D semantic netw
Slide 7: What's Next: Collaboration & Community at Scale
FUTURE DIREGTIONS - PART 1 OF 2 What's Next: Collaboration & Community at Scale A. Enterprise Features Team workspaces with shared knowledge graphs, collaborative annotation, and full session history Role-based access controls and audit trails built for regulated pharmaceutical and clinical environm
Slide 8: What's Next: Deeper Biology, Smarter Tools
FUTURE DIRECTIONS WART 2 OF 2 What's Next: Deeper Biology, Smarter Tools C. Tool Enhancements D. Biology Models Expanded rare cancer disease ontology == with continuously updated molecular & = Broader data modality support: @=== proteomics, transcriptomics & real-world Mobile-optimized interface for
Slide 9: @® withZETA
@® withZETA Multi-agentic Al isn’t the next step in drug development — it’s a fundamental reset of what's possible. withZeta.ai represents our conviction that the greatest breakthroughs in medicine will come from the intersection of human expertise and autonomous scientific intelligence. — Panna Sha